Haleon plc (HLN)vsIndivior PLC Ordinary Shares (INDV)
HLN
Haleon plc
$9.19
-0.33%
HEALTHCARE · Cap: $44.28B
INDV
Indivior PLC Ordinary Shares
$34.49
-0.06%
HEALTHCARE · Cap: $4.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 738% more annual revenue ($11.15B vs $1.33B). INDV leads profitability with a 26.8% profit margin vs 14.5%. INDV trades at a lower P/E of 12.4x. INDV earns a higher WallStSmart Score of 64/100 (C+).
HLN
Buy51
out of 100
Grade: C-
INDV
Buy64
out of 100
Grade: C+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Strong operational efficiency at 46.9%
Earnings expanding 600.0% YoY
Conservative balance sheet, low leverage
Keeps 27 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
Expensive relative to growth rate
2.2% revenue growth
Grey zone — moderate risk
Earnings declined 4.5%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on Price/Book, Operating Margin.
Bull Case : INDV
The strongest argument for INDV centers on Operating Margin, EPS Growth, Debt/Equity. Profitability is solid with margins at 26.8% and operating margin at 46.9%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth, Altman Z-Score.
Bear Case : INDV
The primary concerns for INDV are Altman Z-Score.
Key Dynamics to Monitor
HLN profiles as a value stock while INDV is a mature play — different risk/reward profiles.
INDV carries more volatility with a beta of 1.14 — expect wider price swings.
INDV is growing revenue faster at 13.6% — sustainability is the question.
HLN generates stronger free cash flow (792M), providing more financial flexibility.
Bottom Line
INDV scores higher overall (64/100 vs 51/100), backed by strong 26.8% margins and 13.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, emerging as a spin-off from GlaxoSmithKline, dedicated to providing innovative health solutions through a robust portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. Focused on key segments such as oral care, pain relief, and dietary supplements, Haleon addresses evolving consumer needs while leveraging strong brand equity for sustained market presence. The company's commitment to sustainability and ongoing innovation, alongside strategic investments in product development, positions Haleon favorably for long-term growth and enhanced health outcomes, ultimately maximizing value for shareholders.
Visit Website →Indivior PLC Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company is headquartered in North Chesterfield, Virginia.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?